AR and adenocarcinoma: Notably, the established transdifferentiation model LTL331/331R uniquely captures this dormant phase.[12] The dormant state of LTL331/331R is characterized by a subdued cell cycle capacity (Figure 6A) and a reduced expression of the proliferation marker Ki67 (Figure 6B), coupled with diminished AR/Prostate‐Specific Antigen (PSA) expression indicative of an adenocarcinoma feature, and suppressed Chromogranin A (CHGA)/Cluster of Differentiation 56 (CD56) expression, which represent NE features (Figure 6B).